Cytokinetics reported $43.058 million in third-quarter U.S. MYQORZO net sales on November 4, 2026. As of early November 7 JST, the question is how launch momentum translates into earnings improvement. Company results
MYQORZO, or aficamten, treats adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Thickened heart muscle and excessive contraction restrict blood flow out of the heart. Aficamten inhibits myosin, a molecular motor driving contraction, to reduce that obstruction.
In a 282-person trial, the improvement in peak oxygen uptake, an exercise-capacity measure, exceeded placebo by 1.7 mL/kg/min at 24 weeks. That does not establish a survival benefit. Excessive suppression of contraction can cause heart failure, requiring echocardiograms before and during treatment and a restricted safety program. U.S. prescribing information, revised May 2026
The scenarios cover 2027 U.S. adult oHCM only.
Count treatment time, not just people reached
The company’s “over 2,800 patients dispensed” is cumulative through September. It does not disclose how many are paying, remain on treatment, or will continue throughout 2027. Dividing sales by that count cannot reveal annual net revenue per patient.
A patient-year measures treatment volume: 6,000 people treated for twelve months equal 12,000 treated for six months. More starts need not produce proportionate growth if treatment ends sooner.
The company’s estimate of 120,000 eligible U.S. patients comes through a MarketBeat call transcript; the original audio was not checked. Monitoring, insurance approval and continued paid treatment determine how much potential demand becomes revenue.
Net price can outweigh patient growth
The January company presentation, page 30, lists an annual wholesale acquisition cost of $108,400, before rebates. The graphic’s $60,000–$80,000 annual net prices and 4,000–8,000 patient-years are author assumptions, not disclosed terms or a statistically validated forecast range.
The central case produces $420 million in U.S. net sales. Its benchmark, $172.232 million, simply annualizes Q3 U.S. sales. Assuming 95% gross margin, $40 million in additional commercial costs, unchanged R&D, financing and other costs, and zero incremental tax while company-wide losses continue, modeled earnings improve by about $195 million. Financial filing
At 6,000 patient-years, a $10,000 reduction in annual net price cuts sales by $60 million and the improvement in earnings per share (EPS) by approximately $0.41, holding other assumptions fixed.
Cash payments and accounting expenses differ
Royalty Pharma receives 4.5% on the first $5 billion of worldwide annual aficamten net sales. Payments reduce a financing liability; they are not an equal current-period royalty expense. Separate noncash financing expenses reflect expected future payments. Deducting both as the same expense would double-count. Contract accounting
This model freezes financing costs. But revised expectations increased Q3 noncash expense by $1.8 million. Another $10 million would reduce modeled EPS improvement by roughly $0.07, assuming zero incremental tax and unchanged shares.
The scenarios improve EPS by $0.28, $1.41 and $2.76 using Q3’s weighted-average 139.045 million shares, held fixed. A positive change can simply mean a smaller loss. These are not company-wide EPS forecasts; Q3’s company-wide net loss was approximately $190 million. Future share issuance or dilution could reduce the per-share contribution.
Match the indication before comparing forecasts
Search-retrieved text from MT Newswires’ November 5 report attributes a $500 million 2027 U.S. product-sales estimate to RBC Capital Markets. The article page could not be directly retrieved, and the analyst note was not obtained. Whether it includes the unapproved non-obstructive HCM indication is unclear. No matching company or analyst forecast for U.S. oHCM alone was verified. The gap from $420 million therefore establishes neither relative conservatism nor earnings upside.
Next, watch continued paid treatment, net sales, free supply, inventory, commercial spending, financing expenses and share count. Those disclosures connect an encouraging launch to sustainable earnings.
This article was prepared with assistance from generative AI.